Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.

Professor Andrew Price

You started a new role as Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. What does that entail?

As the Clinical Director in the Trauma and Orthopaedics Directorate I look after the Nuffield Orthopaedics Centre, Orthopaedics and Rheumatology, trauma at the John Radcliffe Hospital, and trauma at the Horton Hospital. I've been doing it since last August and I'm responsible for the day to day running of the directorate, covering clinical care across patients, and staff.

For me, it's all about patient care, putting the patient at the front of it. But also looking after our staff and trying to create a happy working environment. I'm trying to follow the Trust's principles, but at the same time, trying to bring in some of the learning from my time as an academic in terms of innovation, and quality to try and keep moving forward.

What are some of the projects you have been working on?

I've been coordinating the recovery plan to try and get post COVID clinical care back up to normal, and then there's managing the backlog. These are two different things, and we're moving in the right direction.

Working closely with the University I'm helping to identify the musculoskeletal components for the next round of funding from the Biomedical Research Council.

I'm also trying to support digital transformation in the Trust in terms of working with EPR (the electronic patient record) for data collection which will help facilitate research. I'd also like to see an increased use of digital technology in theatre.

We are committed to the Trust and University's principles of improving diversity and equality in opportunities and access, so a part of my role is in supporting inclusivity.

Are you still doing research?

I continue to have academic time at the Botnar and am still heavily involved in research. I've recently secured a grant for a placebo trial to study a novel treatment for osteoarthritis of the knee.

How does your role support the strategy at the Botnar Institute?

I am working closely with Johnny Rees, Director of the Botnar in terms of trying to strengthen the link between the university and the hospital and integrate research from the Botnar into the clinical departments. One of our aims is to be able to recruit our patient population to studies to take the science forward, and then also to take the science and translate it into real care.

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).